A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Active, not recruiting · Phase 1, Phase 2 · NCT06730750
Conditions: Advanced Solid Tumors
At a glance
- Research payments reported, 2025
- $1,139
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 360
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986490 (drug), Bevacizumab (drug)
- Dates
- Started 2025-02-12; completion 2029-12-09
- Results posted
- Not yet
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
From ClinicalTrials.gov, last updated 2026-09-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $1,139 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Heinz-josef Lenz, M.D. Medical Oncology · Los Angeles, CA
- Anwaar M. Saeed, M.D. Medical Oncology · Westwood, KS
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UPMC Hillman Cancer Center $1,031
- Usc Norris Comprehensive Cancer Center $109
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.